Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.64 USD | -.--% | -2.94% | -61.60% |
May. 30 | SAB Biotherapeutics, Inc. Announces Change of Chief Financial Officer | CI |
May. 21 | FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | CI |
Financials (USD)
Sales 2024 * | 922K | Sales 2025 * | - | Capitalization | 24.36M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -47M | EV / Sales 2024 * | 26.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.66
x | P/E ratio 2025 * |
-0.61
x | Employees | 57 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.4% |
1 week | -2.94% | ||
1 month | -38.46% | ||
3 months | -40.81% | ||
6 months | -72.84% | ||
Current year | -61.60% |
Managers | Title | Age | Since |
---|---|---|---|
Eddie Sullivan
FOU | Founder | 58 | 21-10-21 |
Samuel Reich
CEO | Chief Executive Officer | 49 | 21-10-21 |
Michael King
DFI | Director of Finance/CFO | 63 | 23-10-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 68 | 21-10-21 | |
Jeffrey Spragens
BRD | Director/Board Member | 82 | 21-10-21 |
Erick Lucera
BRD | Director/Board Member | 57 | 23-04-02 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 2.64 | -.--% | 4,222 |
24-05-30 | 2.64 | -6.38% | 10,170 |
24-05-29 | 2.82 | +3.68% | 3,400 |
24-05-28 | 2.72 | -.--% | 3,483 |
24-05-24 | 2.72 | +5.02% | 14,480 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-61.60% | 24.36M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- SABS Stock